Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy.

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-03-29 DOI:10.1016/j.trecan.2024.03.003

Robin Demuynck, Yanou Engelen, André G Skirtach, Stefaan C De Smedt, Ine Lentacker, Dmitri V Krysko

引用次数: 0

Abstract

Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.

查看原文本刊更多论文

纳米药物辅助基于免疫原性细胞死亡（ICD）的抗癌疗法。

免疫性细胞死亡（ICD）正在成为抗肿瘤疗法的一个关键组成部分，它能利用患者的免疫系统来对抗癌症。近年来，人们为改进基于免疫细胞死亡的疗法做出了许多努力。在此，我们将讨论基于纳米材料的策略如何提高 ICD 的疗效，并强调其优势和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.